8 completed, 3 active not recruiting, 1 recruiting, 1 unknown. 7 Phase 2, 4 Phase 1, 3 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Active not recruiting 1, Recruiting 1, Unknown 1 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 3 | Active not recruiting 2, Unknown 1 |
| Not applicable | 1 | Withdrawn 1 |
Follow Endometrial Undifferentiated Carcinoma: new trials by email Literature Review of Endometrial Undifferentiated Carcinoma trials Research Report on Endometrial Undifferentiated Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PET/MRI in Endometrial Cancer PET/MRI with radiotracer ([18F]- fluorodeoxyglucose) and a gadolinium-based contrast agent - Cytoreductive Surgery, Grade 3 Endometrial Endometrioid Adenocarcinoma | Not applicable | Withdrawn | Massachusetts General Hospital | 2024-03-30 | 2024-04-02 | |
| Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma Biospecimen Collection, Carboplatin, Computed Tomography - Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 360 | 2022-11-16 | 2026-10-02 |
| Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma Biospecimen Collection, Computed Tomography, Ipilimumab - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 81 | 2022-06-02 | 2026-10-21 |
| Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer Carboplatin, Computed Tomography, Paclitaxel - Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 813 | 2019-08-22 | 2026-10-21 |
| Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy - Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 288 | 2018-09-27 | 2026-10-22 |
| Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer Copanlisib, Laboratory Biomarker Analysis - Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma | Phase 2 | Completed | NRG Oncology | 11 | 2016-09-16 | 2022-02-15 |
| Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Carboplatin, Laboratory Biomarker Analysis, Metformin Hydrochloride - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 / Phase 3 | Unknown | Gynecologic Oncology Group | 469 | 2014-03-17 | 2021-09-30 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel - Cervical Adenocarcinoma, Cervical Adenosarcoma | Phase 1 | Completed | Mayo Clinic | 43 | 2014-02-24 | 2024-07-26 |
| Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Laboratory Biomarker Analysis, Trametinib, Uprosertib - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2013-09-30 | 2020-10-14 |
| Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Dalantercept, Laboratory Biomarker Analysis - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 28 | 2012-09-01 | 2018-03-13 |
| Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Nintedanib - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 37 | 2011-10-01 | 2017-10-09 |
| Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Carboplatin, Dasatinib, Laboratory Biomarker Analysis - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 18 | 2011-09-20 | 2018-04-05 |
| Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Brivanib Alaninate, Laboratory Biomarker Analysis - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 45 | 2009-07-06 | 2017-12-06 |
| Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer Cisplatin, Doxorubicin Hydrochloride, Filgrastim - Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 1 | Completed | Gynecologic Oncology Group | 27 | 2008-01-17 | 2017-08-24 |
Carcinoma, Endometrioid (4) · Endometrial Neoplasms (3) · Carcinosarcoma (2) · Neoplasms (1)
Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Genital Diseases (6) · Genital Diseases, Female (6) · Genital Neoplasms, Female (6) · Neoplasms by Site (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6) · Uterine Neoplasms (6) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Adenocarcinoma (4) · Adnexal Diseases (4) · Carcinoma (4) · Endocrine System Diseases (4)
Paclitaxel (5) · Taxes (5) · Carboplatin (4) · Specimen Handling (3) · Disulfides (2) · Immunoglobulin G (2) · 130-nm albumin-bound paclitaxel (1) · ALK1-Fc fusion protein, human (1) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Biopsy (1) · CTLA-4 Antigen (1) · Cisplatin (1) · Dasatinib (1) · Doxorubicin (1)
National Cancer Institute (NCI) (6) · Gynecologic Oncology Group (5) · Massachusetts General Hospital (1) · Mayo Clinic (1) · NRG Oncology (1)
United States (13) · Canada (2) · Puerto Rico (2) · South Korea (2) · Japan (1)
Alessandro D Santin (1) · Britt K Erickson (1) · D. McMeekin (1) · Don Dizon (1) · Haider S Mahdi (1) · Helen J Mackay (1) · Matthew Powell (1) · Matthew S. Block, M.D., Ph.D. (1) · Onofrio Catalono, MD, PhD (1) · Ramez N Eskander (1) · Robert Coleman (1) · Shannon N Westin (1) · Vicky Makker (1) · Victoria L Bae-Jump (1)
PMID 25312396, PMID 36972022, PMID 37411031, PMID 38127487, PMID 38431043, PMID 40044930, PMID 40966692
U10CA180868 (11), U10CA027469 (6), P50CA098258 (2), P30CA016672 (1), U10CA180830 (1)